solution in methanol Search Results


95
Chem Impex International palmitic acid
Palmitic Acid, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/palmitic acid/product/Chem Impex International
Average 95 stars, based on 1 article reviews
palmitic acid - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

91
Cayman Chemical iso60147

Iso60147, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iso60147/product/Cayman Chemical
Average 91 stars, based on 1 article reviews
iso60147 - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

93
Cayman Chemical cbd
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Cbd, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cbd/product/Cayman Chemical
Average 93 stars, based on 1 article reviews
cbd - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Cayman Chemical azd8055 cayman chemicals 16978
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Azd8055 Cayman Chemicals 16978, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/azd8055 cayman chemicals 16978/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
azd8055 cayman chemicals 16978 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

92
Cayman Chemical n stearoyl taurine
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
N Stearoyl Taurine, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n stearoyl taurine/product/Cayman Chemical
Average 92 stars, based on 1 article reviews
n stearoyl taurine - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

92
Cayman Chemical anisomycin
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Anisomycin, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anisomycin/product/Cayman Chemical
Average 92 stars, based on 1 article reviews
anisomycin - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

92
Cayman Chemical arachidonoyl
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Arachidonoyl, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/arachidonoyl/product/Cayman Chemical
Average 92 stars, based on 1 article reviews
arachidonoyl - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

93
Cayman Chemical ∆ 9 thc
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
∆ 9 Thc, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/∆ 9 thc/product/Cayman Chemical
Average 93 stars, based on 1 article reviews
∆ 9 thc - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Cayman Chemical palmitoyl ethanolamide d4
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Palmitoyl Ethanolamide D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/palmitoyl ethanolamide d4/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
palmitoyl ethanolamide d4 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

91
Revvity methanol
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Methanol, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/methanol/product/Revvity
Average 91 stars, based on 1 article reviews
methanol - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

92
Cayman Chemical trametinib 1 cayman chemical
( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol <t>(CBD)</t> supplementation; or ( iii <t>)</t> <t>methanol</t> (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.
Trametinib 1 Cayman Chemical, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trametinib 1 cayman chemical/product/Cayman Chemical
Average 92 stars, based on 1 article reviews
trametinib 1 cayman chemical - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

Image Search Results


Journal: iScience

Article Title: Mu-opioid receptor selective superagonists produce prolonged respiratory depression

doi: 10.1016/j.isci.2023.107121

Figure Lengend Snippet:

Article Snippet: Morphine , Cayman Chemical , ISO60147.

Techniques: Recombinant, Expressing, Transfection, Software

( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) supplementation; or ( iii ) methanol (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.

Journal: bioRxiv

Article Title: Oviduct fluid metabolic regulation of embryonic genome methylation

doi: 10.1101/2025.06.13.659599

Figure Lengend Snippet: ( A ) Representative in vivo bovine oviduct histoarchitecture at Day 5, showing cannabinoid receptor 1 (CB1) and 2 (CB2) expression. ( B ) Representative control group organoid CB1 and CB2 expression. ( C ) Independent experimental variables – ( i ) 17β-estradiol (E2) with medroxyprogesterone acetate (MPA); ( ii ) E2 and MPA plus Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) supplementation; or ( iii ) methanol (control) supplementation for 144 h. ( D ) Representative organoid brightfield images across treatments and time. Note: Yellow borders are software generated. ( E - G ) Mean (±SEM) organoid (n=4) morphometric kinetics – ( E ) count, ( F ) circularity, and ( G ) area. Select differences observed [ P ≤0.05 (*) and P ≤0.0001 (****)]. ( H ) Representative organoid Ki67 expression following pathological mimic (THC+CBD) supplementation. ( I ) Heatmap of differentially expressed genes (DEG) by treatment, grouped into six clusters. ( J ) Multivariate plot of DEG pathway significance and impact according to cluster. Bubble size is proportional to the impact ratio (number of genes divided by total pathway size), whereas the vertical axis unit is inverse false discovery rate (FDR). ( K - M ) DEG between organoid treatments – ( K ) control vs . E2+MPA, ( L ) control vs . THC+CBD, and ( M ) E2+MPA vs . THC+CBD. Yellow, purple, and teal indicate control, E2+MPA, and THC+CBD gene upregulation, respectively. ( N ) Parametric gene set enrichment analysis using gene ontology resource molecular function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations, highlighting activated (red) and suppressed (blue) processes in E2+MPA vs . THC+CBD treated organoids. All scale bars: 100 µm.

Article Snippet: These were: ( a ) negative control – comprising Base Medium ( Table S2 ); ( b ) E2 – Base Medium supplemented with E2 (Thermo Scientific Chemicals, L0380103) dissolved in methanol (Fisher Chemical, A4521) at a final concentration of 50 nM with a corresponding vehicle contribution of 0.6 % ( v / v ); ( c ) MPA – Base Medium supplemented with MPA (Thermo Scientific Chemicals, 461120010) dissolved in methanol at a final concentration of 1 µM with a corresponding vehicle contribution of 0.3 % ( v / v ); ( d ) Physiological mimic – Base Medium supplemented with both E2 and MPA as above, with a corresponding cumulative vehicle contribution of 0.9 % ( v / v ); ( e ) Pathological mimic – Base Medium supplemented with E2 and MPA as above, in addition to THC (Cayman Chemical, ISO60157) dissolved in methanol at a final concentration of 6 µM with a corresponding vehicle contribution of 0.2 % ( v / v ); and CBD (Cayman Chemical, ISO60156) dissolved in methanol at a final concentration of 6 µM with a corresponding vehicle contribution of 0.2 % ( v / v ); and ( f ) vehicle control – Base Medium supplemented with 1.3 % ( v / v ) methanol – identical to the largest solvent contribution (Group e ).

Techniques: In Vivo, Expressing, Control, Software, Generated